Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial
The optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with...
| 主要な著者: | , , , , , , , , , , , , |
|---|---|
| フォーマット: | Journal article |
| 出版事項: |
American Heart Association
2019
|
| _version_ | 1826294524647833600 |
|---|---|
| author | Rahman, F McEvoy, J Ohkuma, T Marre, M Hamet, P Harrap, S Mancia, G Rodgers, A Rahman, F Selvin, E Williams, B Muntner, P Chalmers, J Woodward, M |
| author_facet | Rahman, F McEvoy, J Ohkuma, T Marre, M Hamet, P Harrap, S Mancia, G Rodgers, A Rahman, F Selvin, E Williams, B Muntner, P Chalmers, J Woodward, M |
| author_sort | Rahman, F |
| collection | OXFORD |
| description | The optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with diabetes mellitus, at moderate-to-high risk, in the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation). Cox models were used to determine whether baseline BP category or CVD risk modified the outcomes of combination perindopril-indapamide treatment, compared with placebo. During 4.3 years of follow-up, treatment with perindopril-indapamide versus placebo reduced mortality and major vascular (macrovascular or microvascular) events. There was no evidence of differences in these effects, regardless of baseline systolic BP (evaluated down to <120 mm Hg; P for heterogeneity, 0.85), diastolic BP (evaluated down to <70 mm Hg; P=0.49), or whether 10-year CVD risk was ≥20% or <20% (P=0.08). The effects of randomized treatment on discontinuation of treatment because of cough or hypotension/dizziness were also statistically consistent across subgroups defined by baseline BP and CVD risk (all P ≥0.08). Adults with diabetes mellitus appear to benefit from more intensive BP treatment even at levels of BP and CVD risk that some guidelines do not currently recommend for intervention. |
| first_indexed | 2024-03-07T03:46:59Z |
| format | Journal article |
| id | oxford-uuid:bfd3d764-fa41-4cf3-b380-f5edf0c9a8c9 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:46:59Z |
| publishDate | 2019 |
| publisher | American Heart Association |
| record_format | dspace |
| spelling | oxford-uuid:bfd3d764-fa41-4cf3-b380-f5edf0c9a8c92022-03-27T05:50:23ZEffects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bfd3d764-fa41-4cf3-b380-f5edf0c9a8c9Symplectic Elements at OxfordAmerican Heart Association2019Rahman, FMcEvoy, JOhkuma, TMarre, MHamet, PHarrap, SMancia, GRodgers, ARahman, FSelvin, EWilliams, BMuntner, PChalmers, JWoodward, MThe optimal blood pressure (BP) goal in patients with diabetes mellitus remains controversial. We examined whether benefits and risks of intensified antihypertensive therapy in diabetes mellitus are influenced by either baseline BP or cardiovascular disease (CVD) risk. We studied 10 948 people with diabetes mellitus, at moderate-to-high risk, in the ADVANCE trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation). Cox models were used to determine whether baseline BP category or CVD risk modified the outcomes of combination perindopril-indapamide treatment, compared with placebo. During 4.3 years of follow-up, treatment with perindopril-indapamide versus placebo reduced mortality and major vascular (macrovascular or microvascular) events. There was no evidence of differences in these effects, regardless of baseline systolic BP (evaluated down to <120 mm Hg; P for heterogeneity, 0.85), diastolic BP (evaluated down to <70 mm Hg; P=0.49), or whether 10-year CVD risk was ≥20% or <20% (P=0.08). The effects of randomized treatment on discontinuation of treatment because of cough or hypotension/dizziness were also statistically consistent across subgroups defined by baseline BP and CVD risk (all P ≥0.08). Adults with diabetes mellitus appear to benefit from more intensive BP treatment even at levels of BP and CVD risk that some guidelines do not currently recommend for intervention. |
| spellingShingle | Rahman, F McEvoy, J Ohkuma, T Marre, M Hamet, P Harrap, S Mancia, G Rodgers, A Rahman, F Selvin, E Williams, B Muntner, P Chalmers, J Woodward, M Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial |
| title | Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial |
| title_full | Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial |
| title_fullStr | Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial |
| title_full_unstemmed | Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial |
| title_short | Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial |
| title_sort | effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus the advance trial |
| work_keys_str_mv | AT rahmanf effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT mcevoyj effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT ohkumat effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT marrem effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT hametp effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT harraps effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT manciag effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT rodgersa effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT rahmanf effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT selvine effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT williamsb effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT muntnerp effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT chalmersj effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial AT woodwardm effectsofbloodpressureloweringonclinicaloutcomesaccordingtobaselinebloodpressureandcardiovascularriskinpatientswithtype2diabetesmellitustheadvancetrial |